A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Authors:

Abstract
8012Background: Elotuzumab is an approved monoclonal antibody targeting SLAMF7 on NK cells and plasma cells that enhances the activity of lenalidomide and bortezomib in multiple myeloma (MM). We studied elotuzumab with pomalidomide, bortezomib, and dexamethasone (elo-PVD) in relapsed and refractory MM. Methods: The primary objective was to determine the overall response rate (ORR). Patients with refractory disease and ≥1 prior lines of treatment (including lenalidomide and a proteasome inhibitor) were eligible to participate. Elotuzumab was weekly for the first 2 cycles and then every other week. Pomalidomide was on days 1-21; bortezomib was on days 1, 8, 15; and dexamethasone was weekly. Each cycle was 28 days. Results: At time of data cutoff, 33 patients (pts) who started treatment were evaluable. The median age was 64 (range 52-79), and the median number of prior regimens was 3 (range 1-9); 27% had high risk FISH. All pts had prior lenalidomide and proteasome inhibitors (bortezomib 94%, 76% carfilzomib...